IceCure Medical Reports Favorable Trial Results for ProSense Cryoablation System in Kidney Cancer Treatment.

IceCure Medical reported favorable trial results for its ProSense Cryoablation System in treating small renal masses in kidney cancer patients. The trial included 114 participants with a median follow-up period of four years, resulting in an 83.9% recurrence-free survival rate. The rate increased to 89.4% in a subgroup of patients with tumors measuring 3 cm or smaller and no prior kidney cancer history. The company's stock is currently trading at $0.59, down 2.58% on the Nasdaq.